Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents

NCT05072080 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT05072080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05072080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Lead sponsor
Bavarian Nordic
Phase
Phase 3
Overall status
Completed
Start date
September 29, 2021
Completion date
April 3, 2023
Enrollment
3,258 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus